Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 585

1.

Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators.

Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.

2.

Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.

Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS; COURAGE Trial Investigators.

J Am Coll Cardiol. 2009 Sep 29;54(14):1303-8. doi: 10.1016/j.jacc.2009.07.013.

3.

Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention.

Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, Dada M, Mancini GB, Hayes SW, O'Rourke RA, Spertus JA, Kostuk W, Gosselin G, Chaitman BR, Knudtson M, Friedman J, Slomka P, Germano G, Bates ER, Teo KK, Boden WE, Berman DS.

Am Heart J. 2012 Aug;164(2):243-50. doi: 10.1016/j.ahj.2012.05.018.

PMID:
22877811
4.

Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.

Maron DJ, Spertus JA, Mancini GB, Hartigan PM, Sedlis SP, Bates ER, Kostuk WJ, Dada M, Berman DS, Shaw LJ, Chaitman BR, Teo KK, O'Rourke RA, Weintraub WS, Boden WE; COURAGE Trial Research Group.

Am J Cardiol. 2009 Oct 15;104(8):1055-62. doi: 10.1016/j.amjcard.2009.05.056. Epub 2009 Aug 28.

PMID:
19801024
5.

Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).

Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS; COURAGE Trial Investigators.

Am J Cardiol. 2009 Jul 1;104(1):1-4. doi: 10.1016/j.amjcard.2009.02.059. Epub 2009 Apr 16.

PMID:
19576311
7.

Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting.

Zellweger MJ, Weinbacher M, Zutter AW, Jeger RV, Mueller-Brand J, Kaiser C, Buser PT, Pfisterer ME.

J Am Coll Cardiol. 2003 Jul 2;42(1):33-40.

10.

Effectiveness of percutaneous coronary intervention in patients with silent myocardial ischemia (post hoc analysis of the COURAGE trial).

Gosselin G, Teo KK, Tanguay JF, Gokhale R, Hartigan PM, Maron DJ, Gupta V, Mancini GB, Bates ER, Chaitman BR, Spertus JA, Kostuk WJ, Dada M, Sedlis SP, Berman DS, Shaw LJ, O'Rourke RA, Weintraub WS, Boden WE; COURAGE Trial Investigators.

Am J Cardiol. 2012 Apr 1;109(7):954-9. doi: 10.1016/j.amjcard.2011.11.023.

PMID:
22445578
11.

Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials.

Fernandez SF, Boden WE.

Curr Atheroscler Rep. 2010 Nov;12(6):423-31. doi: 10.1007/s11883-010-0135-2. Review.

PMID:
20845088
12.

Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization.

Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, Sopko G, Pratt C, Deanfield J, Conti CR.

Circulation. 1997 Apr 15;95(8):2037-43.

13.

Prognostic estimation of coronary artery disease risk with resting perfusion abnormalities and stress ischemia on myocardial perfusion SPECT.

Shaw LJ, Hendel RC, Heller GV, Borges-Neto S, Cerqueira M, Berman DS.

J Nucl Cardiol. 2008 Nov-Dec;15(6):762-73. doi: 10.1007/BF03007357. Epub 2008 Sep 12.

PMID:
18984451
14.

Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary?

Hachamovitch R, Rozanski A, Hayes SW, Thomson LE, Germano G, Friedman JD, Cohen I, Berman DS.

J Nucl Cardiol. 2006 Nov;13(6):768-78.

PMID:
17174808
15.

Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: a randomised controlled trial. The CECaT trial.

Sharples L, Hughes V, Crean A, Dyer M, Buxton M, Goldsmith K, Stone D.

Health Technol Assess. 2007 Dec;11(49):iii-iv, ix-115.

16.

Changes in myocardial ischemic burden following percutaneous coronary intervention of chronic total occlusions.

Safley DM, Koshy S, Grantham JA, Bybee KA, House JA, Kennedy KF, Rutherford BD.

Catheter Cardiovasc Interv. 2011 Sep 1;78(3):337-43. doi: 10.1002/ccd.23002. Epub 2011 Mar 16.

PMID:
21413136
17.

Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.

Coron Artery Dis. 2008 Jun;19(4):271-7. doi: 10.1097/MCA.0b013e3282f487e0.

PMID:
18480672
18.

Results of interventional treatment of stress positive coronary artery disease.

Adamu U, Knollmann D, Alrawashdeh W, Almutairi B, Deserno V, Kleinhans E, Schäfer W, Hoffmann R.

Am J Cardiol. 2010 Jun 1;105(11):1535-9. doi: 10.1016/j.amjcard.2010.01.010. Epub 2010 Apr 8.

PMID:
20494657
19.

Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease.

Sedlis SP, Jurkovitz CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, Maron DJ, Spertus JA, Mancini GB, Teo KK, O'Rourke RA, Boden WE, Weintraub WS; COURAGE Study Investigators.

Am J Cardiol. 2009 Dec 15;104(12):1647-53. doi: 10.1016/j.amjcard.2009.07.043.

PMID:
19962469
20.

Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424.

Boden WE, O'rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Weintraub WS; COURAGE trial coprincipal investigators and study coordinators.

Am Heart J. 2006 Jun;151(6):1173-9.

PMID:
16781214

Supplemental Content

Support Center